Ergoteles’s Ligand Pharmaceuticals LGND Stock Holding History

Ergoteles’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,769	Closed	-$204K	–	1283
2023 Q1	$204K	Sell	2,769 -7,107	-72%	-$505K	0.01%	1007
2022 Q4	$660K	Buy	9,876 +266	+3%	+$17.3K	0.02%	602
2022 Q3	$516K	Buy	+9,610	New	+$565K	0.02%	749
2021 Q3	–	Sell	-3,838	Closed	-$314K	–	1473
2021 Q2	$314K	Sell	3,838 -2,117	-36%	-$176K	0.01%	1047
2021 Q1	$566K	Buy	+5,955	New	+$563K	0.02%	463

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Ergoteles's LGND Position: Q2 2023 in Review

Ergoteles sold out of Ligand Pharmaceuticals (LGND) in Q2 2023, closing a stake of 2,769 shares — an estimated $204K sold.

Ergoteles first reported a position in LGND in Q1 2021 and held it in 5 quarters. The position peaked at $660K in Q4 2022. 204 funds tracked by Wall St. Rank hold LGND as of Q2 2023.

Ergoteles reported no remaining Ligand Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 2,769 Ligand Pharmaceuticals shares in Q2 2023, an estimated $204K.
Ergoteles first reported a position in Ligand Pharmaceuticals in Q1 2021 and held it in 5 quarters.
Ergoteles's Ligand Pharmaceuticals position peaked at $660K in Q4 2022.
204 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.